The Role of Human Decay-Accelerating Factor in the Pathogenesis of Preterm Labor

ABSTRACT

Complement activation is thought to contribute to the pathogenesis of preterm labor (PTL). Decay-accelerating factor (DAF) is a natural complement pathway inhibitor. Our hypothesis was that DAF expression on maternal white blood cells (WBCs) in women with preterm labor is elevated compared with women with no preterm labor. Our secondary objective was to determine if differences in upregulation of DAF levels correlated with clinical outcomes. Serial blood samples were obtained from 30 patients with a clinical diagnosis of PTL and a control group of 30 pregnant individuals (same gestational age range) to determine DAF expression in peripheral WBCs in both groups. DAF expression was higher in women with PTL (less than 37 weeks) compared with the control group without PTL. Subjects with PTL who delivered before 34 weeks had less DAF expression and different kinetics of expression compared with those carrying pregnancies beyond 34 weeks. These data suggest that women with a clinical diagnosis of preterm labor have increased DAF expression on peripheral WBCs. Furthermore, it appears that failure to elevate DAF expression is associated with a risk of early premature delivery.

Preterm labor - complement activation - decay-accelerating factor

REFERENCES

• 1 Hamilton B E, Martin J A, Ventura S J. Births: preliminary data for 2007.  Natl Vital Stat Rep. 2009;  57 1-23
• 2 ACOG Committee on Practice Bulletins. American College of Obstetricians and Gynecologist . ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologist. Number 43, May 2003. Management of preterm labor.  Obstet Gynecol. 2003;  101 (5 Pt 1) 1039-1047
• 3 Joseph K S, Kramer M S, Marcoux S et al.. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994.  N Engl J Med. 1998;  339 1434-1439
• 4 Rooney I A, Morgan B P. Non-lethal doses of antibody and complement stimulate release of prostaglandin E2 from human amniotic cells in vitro.  Biochem Soc Trans. 1990;  18 617
• 5 Hollý I, Handzo I, Dolezalová S, Ponecová M, Králová M, Hucková M. Immunologic parameters in women with threatened premature labor.  Cesk Gynekol. 1993;  58 176-179
• 6 Elimian A, Figueroa R, Canterino J, Verma U, Aguero-Rosenfeld M, Tejani N. Amniotic fluid complement C3 as a marker of intra-amniotic infection.  Obstet Gynecol. 1998;  92 72-76
• 7 Brodbeck W G, Kuttner-Kondo L, Mold C, Medof M E. Structure/function studies of human decay-accelerating factor.  Immunology. 2000;  101 104-111
• 8 Hasan R J, Pawelczyk E, Urvil P T et al.. Structure-function analysis of decay-accelerating factor: identification of residues important for binding of the Escherichia coli Dr adhesin and complement regulation.  Infect Immun. 2002;  70 4485-4493
• 9 Lublin D M, Coyne K E. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.  J Exp Med. 1991;  174 35-44
• 10 Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.  J Immunol. 1993;  151 1562-1570
• 11 Cunningham D S, Tichenor Jr J R. Decay-accelerating factor protects human trophoblast from complement-mediated attack.  Clin Immunol Immunopathol. 1995;  74 156-161
• 12 Holmes C H, Simpson K L, Wainwright S D et al.. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.  J Immunol. 1990;  144 3099-3105
• 13 Xu C, Mao D, Holers V M, Palanca B, Cheng A M, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance.  Science. 2000;  287 498-501
• 14 Nowicki S, Izban M G, Pawelczyk E et al.. Preterm labor: CD55 in maternal blood leukocytes.  Am J Reprod Immunol. 2009;  61 360-367
• 15 Kaul A, Nagamani M, Nowicki B. Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect.  Am J Reprod Immunol. 1995;  34 236-240
• 16 Bétis F, Brest P, Hofman V et al.. Afa/Dr diffusely adhering Escherichia coli infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr adhesins.  Infect Immun. 2003;  71 1774-1783
• 17 Blok V T, Gelderman K A, Tijsma O H, Daha M R, Gorter A. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.  Scand J Immunol. 2003;  57 591-599